Company Description
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects.
Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will be pursuing a second Phase III trial to meet agreed upon FDA standards.
Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, we intend to submit a Biologics License Application for Apitox.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erik Emerson |
Contact Details
Address: 2 East Broad Street 2nd Floor Hopewell, NJ 08425 United States | |
| Phone | 925-872-6429 |
| Website | apimedsus.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001894525 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher Kim, MD | Chairman and Chief Medical Officer |
| Erik Emerson | Chief Executive Officer and Chief Financial Officer |
| Jakap Koo | Director |
| Dr. Bennett Weintraub, PhD. | Director |
| Hankil Yoon | Director |
| Carol O’Donnell | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 25, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 5, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 17, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 13, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 29, 2024 | DRS | [Cover] Draft Registration Statement |